Home » Stocks » UPC

Universe Pharmaceuticals, Inc. (UPC)

Universe Pharmaceuticals will go public soon, but the exact IPO date is still unknown.
Stock Price: $5.00 - $7.00
Current IPO price range

Stock Price Chart

Key Info

Market Cap 126.00M
Revenue (ttm) 31.49M
Net Income (ttm) 8.55M
Shares Out 21.00M
EPS (ttm) 0.41
PE Ratio 14.74
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day n/a
Last Price n/a
Previous Close n/a
Change ($) n/a
Change (%) n/a
Day's Open n/a
Day's Range n/a
Day's Volume n/a
52-Week Range n/a

More Stats

Market Cap 126.00M
Enterprise Value n/a
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 21.00M
Float n/a
EPS (basic) n/a
EPS (diluted) 0.41
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield 6.79%
FCF Yield n/a
Payout Ratio n/a
Shares Short n/a
Short Ratio n/a
Short % of Float n/a
Beta n/a
PE Ratio 14.74
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 4.00
PB Ratio n/a
Revenue 31.49M
Operating Income n/a
Net Income 8.55M
Free Cash Flow n/a
Net Cash n/a
Net Cash / Share n/a
Gross Margin n/a
Operating Margin n/a
Profit Margin 27.15%
FCF Margin n/a
ROA n/a
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$n/a*
*No analysts have provided price targets for this stock.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018
Revenue33.2328.51
Revenue Growth16.54%-
Net Income / Loss7.557.60
Earnings Growth-0.68%-
Numbers in millions USD.

Company Profile

Company Details

Full Name Universe Pharmaceuticals, Inc.
Country China
Employees 176
CEO Gang Lai

Stock Information

Ticker Symbol UPC
Stock Exchange NASDAQ
Unique Identifier NASDAQ: UPC
IPO Date Pending

Description

Universe Pharmaceuticals is a pharmaceutical company based in Jiangxi, China, specializing in the manufacturing, marketing, sales and distribution of traditional Chinese medicine derivatives (“TCMD”) products targeting the elderly with the goal of addressing their physical conditions in the aging process and to promote their general well-being. We have registered and obtained approval for 26 varieties of TCMD products from the National Medical Products Administration (the “NMPA”), and we currently produce 13 varieties of TCMD products, which are sold in approximately 249 cities of 30 provinces in China as of the date of this prospectus. In addition, through our wholly-owned subsidiary Jiangxi Universe Pharmaceuticals Commercial Trade Co., Ltd. (“Universe Trade”), we sell not only our TCMD products, but also biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces (“TCMPs”), and dietary supplements manufactured by third-party pharmaceutical companies.